HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Chihiro Naito Selected Research

1,2- dipalmitoyl- 3- phosphatidylethanolamine

2/2018Development of PEGylated aspartic acid-modified liposome as a bone-targeting carrier for the delivery of paclitaxel and treatment of bone metastasis.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Chihiro Naito Research Topics

Disease

1Osteoporosis
11/2018
1Neoplasm Metastasis (Metastasis)
02/2018
1Neoplasms (Cancer)
02/2018

Drug/Important Bio-Agent (IBA)

1Hyaluronic Acid (Hyaluronan)IBA
11/2018
1Teriparatide (Parathar)FDA Link
11/2018
11,2- dipalmitoyl- 3- phosphatidylethanolamineIBA
02/2018
1Polyethylene Glycols (Polyethylene Glycol)FDA LinkGeneric
02/2018
1Paclitaxel (Taxol)FDA LinkGeneric
02/2018
1Liposomes (Liposome)IBA
02/2018
1tesmilifene (DPPE)IBA
02/2018
1Aspartic Acid (Aspartate)FDA Link
02/2018

Therapy/Procedure

1Subcutaneous Injections
11/2018
1Intravenous Injections
02/2018